Syndax Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Syndax (SNDX)
SNDX shareholders saw the market open to losses of more than 11% after the Phase 2 MAXPIRe trial of axatilimab missed its primary endpoint in idiopathic pulmonary fibrosis. SueWallSt notifies investors of a pending investigation into potential securities law violations on behalf of...
Read original article on All News Releases →